Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
 

 

Target Validation Information
TTD IDTTDC00048
Target NameInduced myeloid leukemia cell differentiation protein Mcl-1    
Type of TargetClinical trial target    
Drug Potency against TargetAT-101IC50 = 180 nM[1]
TW-37IC50 = 1030 nM[2]
LIOTHYRONINE SODIUMIC50 = 14687.4 nM[3]
CEPHALOCHROMINIC50 = 1491.9 nM[3]
SULFURETINIC50 = 1534.63 nM[3]
AMENTOFLAVONEIC50 = 1634.07 nM[3]
BITHIONOLIC50 = 1898.89 nM[3]
GNF-PF-1591IC50 = 19733.2 nM[3]
ROSMARINIC ACIDIC50 = 2025.72 nM[3]
MORINIC50 = 2988.26 nM[3]
GNF-PF-3955IC50 = 3567.91 nM[3]
NSC-180246IC50 = 3944.08 nM[3]
ALTENUSINIC50 = 4147.65 nM[3]
QEDIIRNIARHLAQVGDSMDRIC50 = 52 nM[2]
NSC-66209IC50 = 5376.77 nM[3]
GNF-PF-5134IC50 = 9187.06 nM[3]
Action against Disease ModelAT-101When administered alone, AT-101 resulted in increased apoptosis in concentration-dependent manner against both radiotherapy responsive (HCC2429) and non-responsive (A549) cell-lines, with enhanced activity in HCC2429 even at lower concentration. Furthermore, AT-101 promoted radiosensitivity of A549 and HCC2429 cells (p < 0.005). Consistent with 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazoli uM bromide assay findings, A549 cells required increased AT-101 dose to achieve a similar cytoxicity to HCC2429 cells[4]
The Effect of Target Knockout, Knockdown or Genetic VariationsAdministration of ABT-737 to Mcl-1 knockout mice induced severe liver apoptosis, suggesting that t uMor-specific inhibition of Mcl-1 is required for therapeutic purposes[5]
Ref 1Nat Rev Drug Discov. 2008 Dec;7(12):989-1000.BCL-2 family antagonists for cancer therapy. To Reference
Ref 2J Med Chem. 2006 Oct 19;49(21):6139-42.Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. To Reference
Ref 3Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. Epub 2010 Oct 21.In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). To Reference
Ref 4J Thorac Oncol. 2010 May;5(5):680-7.AT-101, a pan-Bcl-2 inhibitor, leads to radiosensitization of non-small cell lung cancer. To Reference
Ref 5Hepatology. 2010 Oct;52(4):1310-21.The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

 
   
           
 
Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543